Eli Lilly and CompanyvsSunshine Biopharma

LLY and SBFM stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,429.81

Value $1.35T

-0.27%
LLY's page

SBFM

Sunshine Biopharma Inc.

$2.55

Value $2.1M

-0.96%
SBFM's page

Eli Lilly and Company (LLY) has a market value of $1.35T and Sunshine Biopharma (SBFM) $2.1M. Over the last year, with dividends, LLY moved +40.1% and SBFM -99.2%. Dividend yield: LLY 0.44%, SBFM none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.35T

    SBFM$2.1M

    LLY is 642,105 times SBFM

  • Revenue, 12 months

    LLY$86.5B

    SBFM$35M

    LLY is 2,444 times SBFM

  • Net income, 12 months

    LLY$27.6B

    SBFM-$6.2M

  • Operating margin

    LLY–

    SBFM-17.2%

  • ROIC

    LLY35.5%

    SBFM-19.3%

    54.7 points apart

  • P/E

    LLY48.9

    SBFM–

  • Dividend yield

    LLY0.4%

    SBFM0.0%

    0.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+146.1%

SBFM-100.0%

0100200202420252026
Returns by period
PeriodLLYWith dividendsSBFMWith dividends
1 year since November 14, 2025+40.1%Price +39.3%-99.2%Price -99.2%
3 years since November 17, 2023+146.1%+35.0% a yearPrice +141.3%-100.0%-97.1% a yearPrice -100.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanySBFMSunshine Biopharma

Valuation

LLYSBFM
Valuation
Price$1,429.81$2.55
Market value$1.35T$2.1M
Enterprise value (EV)$1.39T–
P/E48.9–
P/E, 5-year median49.9–
P/B33.50.1
EV/EBIT40.1–
Free cash flow yield1.5%–

Results and growth

LLYSBFM
Results and growth
Revenue, 12 months$86.5B$35M
Net income, 12 months$27.6B-$6.2M
Free cash flow, 12 months$19.7B-$6.0M
Earnings per share, 12 months$30.81-$170.83
Revenue growth, year on year44.7%4.1%
Revenue growth a year, past+21.6%over 5 years+247.7%over 5 years
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYSBFM
Margins and returns on capital
Gross margin83.6%30.4%
Operating margin–-17.2%
Net margin31.9%-17.5%
ROIC35.5%-19.3%
ROE88.6%-24.7%

Balance sheet

LLYSBFM
Balance sheet
Cash$4.9B$15M
Total debt$49.5B$627.6K
Net debt / EBITDA1.2–
Interest cover38.9×–

Dividends and buybacks

LLYSBFM
Dividends and buybacks
Dividend yield0.4%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%–
Shareholder yield0.7%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or SBFM

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or Sunshine Biopharma?

By market value, Eli Lilly and Company ($1.35T) is about 642,104.7 times Sunshine Biopharma ($2.1M), at today's prices.

How did LLY and SBFM stock do over the last 3 years?

Since November 17, 2023, LLY's price moved +141.3% and SBFM's -100.0%. With dividends: LLY +146.1% (+35.0% a year), SBFM -100.0% (-97.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or SBFM?

The dividend yield at today's price is 0.44% for Eli Lilly and Company and none for Sunshine Biopharma. Over the last twelve months they paid $6.34 and – per share.

Which has the higher profit margins, Eli Lilly and Company or Sunshine Biopharma?

Over the last twelve months, the net margin was 31.9% for Eli Lilly and Company and -17.5% for Sunshine Biopharma, and the operating margin – and -17.2%. Revenue was $86.5B and $35M.

Which is the better investment, Eli Lilly and Company or Sunshine Biopharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.